News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>BOCOMI Lifts NIO-SW (09866.HK) TP to $62.7, Keeps Rating at Buy
NIO-SW (09866.HK)(NIO.US)'s 2Q25 revenue was approx. RMB19.01 billion, up 9% YoY, with an auto revenue of around RMB16.3 billion, in line with market expectations, according to...
Reset
Send
The window will close in 5 seconds
<Research>BOCOMI Lifts NIO-SW (09866.HK) TP to $62.7, Keeps Rating at Buy
Close
Recommend
7
Positive
7
Negative
8
 
SHORT SELL
 
STOCK INFO

NIO-SW (09866.HK)  -0.400 (-0.829%)    Short selling $222.48M; Ratio 46.433%   (NIO.US)      's 2Q25 revenue was approx. RMB19.01 billion, up 9% YoY, with an auto revenue of around RMB16.3 billion, in line with market expectations, according to BOCOMI's research report.

Looking ahead to 4Q25, NIO-SW aims for a combined monthly sales target of about 50,000 units for NIO and Onvo, with a gross margin improvement to 17-18%.

Related NewsJPM Maintains Overweight on NIO (NIO.US) despite 2Q Results Miss
BOCOMI believed that a rebound in sales will boost market confidence, benefiting future new car launches and subsequent financing. Based on adjusted revenue forecasts, the broker lifted its target prices for NIO-SW's H-shares/ US stock to $62.7/ US$8, corresponding to a projected 2025 PS ratio of 1.2x, with rating kept at Buy.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-09-05 16:25.) (Real-time Streaming US Stocks Quote; Except All OTC quotes are at least 15 minutes delayed.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.